

# Meeting the Moment


Wafaa El-Sadr





## Outline of Presentation

- Status of the HIV epidemic
- Current challenges
- Anticipated impact
- Available assets
- Way forward
- Conclusions

## Great progress has been made in confronting HIV








# Percent change in annual in number of HIV deaths (2010 and 2023)



Source: UNAIDS epidemiological estimates, 2024 (https://aidsinfo.unaids.org/).


# Global Scale-Up of HIV Treatment



Number of people living with HIV who are on antiretroviral treatment (ART), by world region (in 1,000s)


# Annual HIV/AIDS deaths averted by antiretroviral therapy, World







## A Global Epidemic





## However, challenges remain.....

## **Globally:**


- Not on track to meet prevention targets
- Nearly 25% of PWH not on treatment
- Progress lagging for specific geographies and groups:
  - Asia, Latin America, Eastern Europe and Central Asia, and Middle East and North Africa
  - Adolescent girls and young women
  - Key populations
  - Infants and children



## At the same time in 2025, we face new challenges

### U.S. spending in billions







Source: KFF analysis of data from the Office of Management and Budget, Agency Congressional Budget Justifications, Congressional Appropriations Bills, and U.S. Foreign Assistance Dashboard [website], available at: www.foreignassistance.gov. • Get the data • Download PNG



## HIV Funding Sources, CQUIN member countries



# CQUIN member countries – vulnerability to external funding cuts



# Projected impact from different models for variable periods of time

## **UNAIDS Predictions**

UNAIDS predicts, by 2030:

- 4.2 million additional deaths
- 6.6 million additional HIV infections
- 3.4 million additional children orphaned

Should HIV programs previously supported by the PEPFAR be permanently discontinued

	Workbook	Goals model from Avenir Health	Optima model from Burnet Institute	HIV Modelling Consortium
Period covered	2025–2029	2025-2029	2025–2030	2025–2040
Countries covered	55 PEPFAR supported countries	55 PEPFAR supported countries	26 countries, 14 of which were supported by PEPFAR	55 countries used for Goals, 13 for Optima and 1–4 countries for the other models
Assumed change	All PEPFAR supported activities are permanently discontinued	All PEPFAR supported activities are permanently discontinued	All PEPFAR and other funding sources are reduced	Complete cessation of US funding and programmes
Additional new HIV infections	8.7 million	6.6 million	4.4 million- 10.7 million	15 million
Additional AIDS- related deaths	6.3 million	4.2 million	0.8 million to 2.9 million	28 million
Comments	This calculation used the number of people reached with services to determine impact	This model used the proportion of total HIV expenditure paid for by PEPFAR to reduce prevention and treatment coverage	Results also provided if mitigation efforts are undertaken	This model used the averages from six HIV models (including Goals and Optima).

UNAIDS (April 2025)

# Impact on the US Epidemic


With halting of national HIV prevention efforts, modelling estimates indicate an increase between 2025 and 2030 in:

- Number of new infections by over
   213,300
- Number of total deaths by over 10,600



# Funding decisions reach beyond HIV

### Terminated share of Global Health Awards, by Sub-sector



Source: KFF analysis of terminated and active awards included in a list the Trump Administration recently sent to Congress and data available on ForeignAssistance.gov.



# We have come a long way....













# We are in a different place...


### We have:

- ✓ Deeper skills and experience
- ✓ Stronger structures and systems
- ✓ Better diagnostic and monitoring tests and strategies
- More prevention methods
- ✓ Better drugs for treatment
- ✓ More effective methods for prevention of vertical transmission
- ✓ Novel service delivery models (DSD)
- ✓ Strong community leadership
- ✓ Stronger procurement and laboratory systems
- ✓ Robust monitoring and evaluation systems
- A transformed health system



# Testing and linkage

- Status-neutral approach
- Self-testing
- Duo-testing
- DSD for testing





**Bioline™** 

**HIV/SYPHILIS DUO** 

444

Abbott
HIV/Syphilis
Duo

-


◆ SP10 / WB 20 µI



## **HIV Prevention:** New methods and modalities

- Novel long-acting antiretroviral methods and delivery systems
- Integrated multi-purpose prevention technologies (MPT)
- Broadly neutralizing antibodies
- U=U
- Differentiated service delivery models







## **HIV Treatment:** New methods and modalities

- Once daily dosing
- Long-acting antiretrovirals
- Dispersible dolutegravir for children
- Differentiated service delivery models










## CQUIN: Progress in DSD for ART (2017-2021)



#### The 5 stages of the capability maturity model:

Early or preliminary stages of planning and development; useful in identifying next steps to take in the scale-up process

Work has begun and the initial efforts are ongoing; highlights areas that can be prioritized for improvement


Efforts have resulted in measurable progress, such as a draft for review of achievement of more than 25% progress to a target

Considerable progress has been made, resulting in over 50% progress to a target or working systems only in need of finalization


Achievement of a highly-evolved implementation; further improvements and refinements can be made as needed

# **Community Engagement**

- Community Advocacy **Networks**
- Systematic assessment of community engagement
- Community-led monitoring



# What is the best we can do with the resources we have?



## **Consensus strategies:**

- Use modeling, community consultation, and intersectoral planning to redefine the core package
  - Clinical and psychosocial services
  - Laboratory services (diagnostic and monitoring)
  - M&E indicators
- Leaner, more efficient and more integrated programs
  - Integration of HIV programs into national health systems
  - Integration of HIV services into routine and/or chronic health care service delivery models
- Country-owned and community-driven health services

# **Prioritizing HIV Services**

### **Health Products - Considerations on deprioritization**

#### Consider deprioritizing:

#### · HIV Treatment, Care and Support:

- Cotrimoxazole continuation for those stable on ART in line with WHO guidance
- Active Hep B case finding and management among adults (could be supported in high prevalence settings among people at higher risk)
- Hep C testing and management as part of HIV or harm reduction services in countries with lower levels of coinfection
- · New cervical cancer screening initiatives
- Treatments for non-communicable diseases (NCDs)
- HIV drug resistance surveys and surveillance can be deferred until resources are available
- In some countri economize in th although Global

#### • TB/HIV:

- Procurement of
- Procurement of
- IGRA and skin t

#### Elimination of Vertical

- Hep B testing co
- Investments in in networks to con

#### · HIV Testing:

- Higher cost test concurrently or
- Higher cost HIV market

#### • HIV Prevention:

- PrEP ring for ne TDF/3TC;
- Female condon



# GC7 Programmatic Reprioritization Approach

Home tracing if no res

Home tracing if not re (re)started ART stage pregnant and breastfe

Home tracing if no res their scheduled appoin

results

Date published: 16 May 2025 (interim version)

Date updated: 6 June 2025 (full version)

# Tool for Intervention Evaluation and Ranking (TIER)

THIS IS A DRAFT FOR CONSIDERATION AND INPUTS							
	SCENARIO 1	SCENARIO 2	SCENARIO 3	SCENARIO 4			
	A high-burden	A high-burde	A high-burden c	A low-burden o			
	Limited, possil	Adolescent g	Clinically unstab	Clinically unstal			
tails at every clinical visit or ART refill collection	Minimum	Minimum	Minimum	Minimum			
ts with abnormal lab results	Minimum	Minimum	Minimum	Minimum			
following groups who have missed their it by more than 7/14/28 days: those with active tage 4, CD4 <200, children and adolescents, eding women	Minimum	Minimum	Minimum	Minimum			
ho have missed their scheduled appointment by	Standard	Standard	Standard	Optimal			
sponse to calls for clients with abnormal lab	Standard	Standard	Standard	Optimal			
esponse to phone calls: those with active OIs, e 4, CD4 <200, children and adolescents, eeding women	Standard	Standard	Standard	Optimal			
sponse to phone calls for all who have missed intment by more than 28 days	Optimal	Optimal	Optimal	Optimal			

# Prioritizing HIV indicators

### **VALUE OF INFORMATION**



**Clinically significant\*** 



Impacts epidemiology of HIV (population-level)



Provides critical early warning signal



**Enables managers to address important gaps** 



Provides relevant evidence for community and researchers

\*and included in the national package of HIV services

### **CONTEXTUAL FACTORS**



Disease burden, morbidity, mortality



Resources *needed* to document, manage, and use data



Resources *available* to document, manage, and use data



Capacity of program/stakeholders to use data for action



Confidentiality and security of information, and risks of breach

## Integration of HIV Services into Primary Care

### Systems: Integration at the health system level


The assimilation of health interventions into each of the critical functions of a health system - Atun et al.

 For example: Governance/stewardship, policies, financing, supply chain, laboratory systems, healthcare workforce, standards and quality management, health information systems


# Services: Integration at the point of service (models of care)

Joining together different kinds of services or operational programmes to maximize outcomes — UNAIDS

- HIV clinical, lab, pharmacy and support **services co- located** with those for other health conditions
- HIV services provided by the same health workers as those for other health conditions
- HIV services documented & monitored with the same systems used for other health condition



Integration of HIV Services into Primary Care (non-HIV Programs)




# A Unique Assets: CQUIN and HIVE



**HIVE:** Kenya, Mozambique, Nigeria, South Africa, Zambia, Tanzania

### **PATA Supported countries:**

Mozambique, Nigeria, South Africa



## **Way Forward**





Country-to-country support and cross-learning



Shared resources, tools and strategies, including those from WHO, GF, IAS, and ITPC




CQUIN communities of practice, refined for the current context



CQUIN and HIVE-specific tools (e.g. frameworks, prioritized services, prioritized HIV program indicators, capability maturity models, minimum)

## Principles to hold on to:

- Innovation
- Quality
- Community engagement& leadership
- Person-centered services
- Impact
- Efficiency




## Conclusions

- Sudden and profound changes in the past months have major implications for recipients of services, both children and adults, and HIV programs
- This moment compels coming together to preserve the gains and maintain the momentum in the HIV response
- The urgency now is to streamline systems and prioritize services and indicators, while maintaining the principles that have guided our work
- Scenario planning is necessary, with the need for iterative adjustments based on evolving information and ongoing review of critical data points
- The CQUIN and HIVE communities are uniquely positioned to advance the response to this moment







# Thank You!

